Top Research Reports for Accenture, Sanofi & Dell Technologies

Monday, November 10, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture plc (ACN), Sanofi (SNY) and Dell Technologies Inc. (DELL). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Up as Government Shutdown Looks to EndToday's Featured Research ReportsShares of Accenture have underperformed the Zacks Computers - IT Services industry over the past year (-31.2% vs. -18.7%). The company is facing rising competition, which has led to increased talent costs and pricing pressures. Rapid acquisitions have made the company prone to integration risks. The Zacks analyst has a Neutral recommendation on the stock, and would advise a cheaper entry for investors.Nevertheless, Accenture’s growth strategy focuses on delivering 360-degree value to stakeholders, which is an attractive aspect for the firm. This consulting services provider thrives on the robust demand for application modernization and maintenance, cloud enhancements, and cybersecurity. Over the years, Accenture has leveraged buyouts to strengthen digital technology and capital project capabilities. Its cash position allows the company to explore different markets. Dividend-seeking investors will find this stock appealing. Also, its liquidity position is a tailwind. (You can read the full research report on Accenture here >>>)Sanofi’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+2.2% vs. +0.8%). The company beat third-quarter estimates for earnings and sales. Dupixent is a key top-line driver for Sanofi, as it enjoys strong demand across all approved indications and geographies. Sanofi possesses a leading vaccine portfolio. Several new drugs were launched in the past couple of years that have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi has increased R&D investments and is achieving significant progress with its pipeline. It has also been active on the M&A front. However, the generic erosion of Aubagio in all key markets, and lower sales from other mature products are hurting sales. Other headwinds include competitive pressure on influenza vaccines, regular pipeline setbacks and uncertainties from potential U.S. tariffs on EU exports.(You can read the full research report on Sanofi here >>>)Shares of Dell Technologies have outperformed the Zacks Computer - Micro Computers industry over the year-to-date period (+25.2% vs. +8%). The company is benefiting from strong demand for AI servers, driven by ongoing digital transformation and heightened interest in generative AI applications. It secured $8.2 billion in AI server orders, surpassing shipments and building a strong backlog. Strong enterprise demand for AI-optimized servers aids DELL. A robust partner base that includes NVIDIA, Google and Microsoft has been a major growth driver. However, the company is facing a challenging macroeconomic environment, along with stiff competition in the PC market from companies like HP and Lenovo.Dell Technologies faces challenges from weaker demand for traditional servers and storage in North America, slower federal spending, and declining consumer PC revenue. Supply-chain costs and competitive pressures in the AI market are also impacting profitability.(You can read the full research report on Dell Technologies here >>>)Other noteworthy reports we are featuring today include Public Service Enterprise Group Inc. (PEG), PG&E Corp. (PCG) and Cenovus Energy Inc. (CVE).Mark VickerySenior EditorNote: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadAccenture (ACN) Gains From Service Demand, Talent Cost AilsDupixent to Remain Sanofi's (SNY) Key Top-Line DriverSolid Demand for AI Servers Aids Dell Technologies (DELL)Featured ReportsInvestments and Renewable Energy Focus Aid Public Service (PEG)According to the Zacks analyst, Public Service aims regulated capital investments of $21-$24 billion, which should further strengthen its operations and expand its renewable portfolio.Investments Aid PG and E Corporation (PCG) Amid Poor SolvencyPer the Zacks analyst, PGE Corporation makes systematic investments to maintain and upgrade the reliability of its infrastructure. Yet its poor financial ratios indicate weak solvency position.Cenovus (CVE) Set to Benefit from West White Rose StartupPer the Zacks analyst, Cenovus shows strong resilience and execution, rapidly rebounding from wildfire impacts as West White Rose nears completion, positioning it for solid growth into 2026.Strong Product Portfolio Aids DexCom (DXCM) Fight CompetitionPer the Zacks analyst, DexCom strong product portfolio targeting the large and growing diabetes market is helping the company fight intensifying competition with entry new competing products.Robust Infrastructure Spends Aid MasTec (MTZ), Project Delays HurtPer the Zacks analyst, MasTec is gaining from robust booking trends amid an increased public spending environment. However, project delays related to Greenlink and macro risks hurt prospects.Strong Americas Unit Drives Allegion (ALLE), High Debt HurtsPer the Zacks analyst, solid traction of Allegion's Americas segment, driven by strength in non-residential and electronics end markets, will drive its growth. High debt level is concerning.Assurant (AIZ) Gains on Solid Premiums Amid Escalating CostsPer the Zacks analyst, Assurant is set to grow on solid Global Lifestyle and Global Lifestyle segments, which will drive improvement in earned premiums and fees. However, high costs remain a concern.New UpgradesQualys (QLYS) Rides on Product Strength, Marketing EffortsPer the Zacks analyst, Qualys benefits from expanding product capabilities, which helps it gain customers. Increasing marketing efforts are also an upside.Telephone and Data Systems Rides on Strong Fiber DemandPer the Zacks analyst, steady growth in fiber broadband connections and healthy demand in tower rental business will likely drive Telephone and Data Systems' top line.PRA Group Rides on Growing Portfolio Income and Cash CollectionsPer the Zacks analyst, PRA Group's rising portfolio income from higher purchases and increasing cash collections are expected to boost its top line.New DowngradesGolar LNG (GLNG) Grapples With High Vessel Operating CostsThe Zacks Analyst is worried about the escalating vessel operating expenses as they are likely to keep the bottom line under pressure.Archer Daniels' (ADM) Carbohydrate Solutions Unit Remains SoftPer the Zacks analyst, Archer Daniels' Carbohydrate Solutions unit has been sluggish. Softness in sweeteners and starches with lower demand and persistent high corn costs have weighed on performance.Elevated Expenses, Margin Pressure to Hurt Bank OZK (OZK)Per the Zacks analyst, Bank OZK's expansion efforts will likely result in higher costs, thus hurting profits. Pressure on net interest margin because of the interest rate cuts is another concern.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Accenture PLC (ACN): Free Stock Analysis Report Public Service Enterprise Group Incorporated (PEG): Free Stock Analysis Report Pacific Gas & Electric Co. (PCG): Free Stock Analysis Report Dell Technologies Inc. (DELL): Free Stock Analysis Report Cenovus Energy Inc (CVE): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks